Stock VBIV VBI VACCINES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company VBI Vaccines Inc.

Equities

VBIV

CA91822J2020

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.6297 USD +3.40% Intraday chart for VBI Vaccines Inc. +4.95% +7.18%
Apr. 16 VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 15 North American Morning Briefing : Stock Futures -2- DJ

Business Summary

VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

Number of employees: 193

Sales per Business

USD in Million2022Weight2023Weight Delta
License
41.4 %
- - 4 41.4 % -
Vaccines
35.8 %
1 86.0 % 3 35.8 % +233.73%
Research & Development Service
22.8 %
0 14.0 % 2 22.8 % +1,210.60%

Sales per region

USD in Million2022Weight2023Weight Delta
China/Hong Kong
64.3 %
0 6.1 % 6 64.3 % +8,362.12%
United States
21.3 %
1 64.2 % 2 21.3 % +165.47%
Europe
12.5 %
0 0.6 % 1 12.5 % +17,983.33%
Israel
1.9 %
0 29.1 % 0 1.9 % -46.98%

Managers

Managers TitleAgeSince
Jeff Baxter CEO
 Chief Executive Officer 62 16-04-30
Nell Beattie DFI
 Director of Finance/CFO 36 15-07-08
David Anderson CTO
 Chief Tech/Sci/R&D Officer 54 16-05-05
Francisco Diaz-Mitoma CTO
 Chief Tech/Sci/R&D Officer 69 16-01-31
Nicole Anderson IRC
 Investor Relations Contact - 17-09-30
Athena Kartsaklis PRN
 Corporate Officer/Principal 59 17-05-22
Misha Nossov PRN
 Corporate Officer/Principal - 10-04-30
John Dillman PRN
 Corporate Officer/Principal 56 22-07-11
Avi Mazaltov PRN
 Corporate Officer/Principal 62 17-03-29
T. Buckley PRN
 Corporate Officer/Principal 48 00-12-31

Members of the board

Members of the board TitleAgeSince
Vaughn Himes BRD
 Director/Board Member 63 23-04-23
Steven Gillis CHM
 Chairman 71 04-12-31
Jeff Baxter CEO
 Chief Executive Officer 62 16-04-30
Damian Braga BRD
 Director/Board Member 68 20-03-08
Michel de Wilde BRD
 Director/Board Member 74 16-04-30
Blaine McKee BRD
 Director/Board Member 59 19-01-10
Nell Beattie DFI
 Director of Finance/CFO 36 15-07-08
Joanne Cordeiro BRD
 Director/Board Member 66 19-04-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 28,432,275 24,873,465 ( 87.48 %) 0 87.48 %

Shareholders

NameEquities%Valuation
Perceptive Advisors LLC
5.832 %
1,381,355 5.832 % 832 957 $
Perceptive Advisors LLC
5.326 %
1,261,710 5.326 % 760 811 $
ARCH Venture Partners LLC
4.404 %
1,043,292 4.404 % 629 105 $
Alyeska Investment Group LP
2.645 %
626,436 2.645 % 377 741 $
Brii Biosciences Ltd.
1.322 %
313,265 1.322 % 188 899 $
Vanguard Group, Inc. (Subfiler)
0.7786 %
184,436 0.7786 % 111 215 $
Geode Capital Management LLC
0.5857 %
138,729 0.5857 % 83 654 $
BlackRock Institutional Trust Co. NA
0.4727 %
111,960 0.4727 % 67 512 $
Cambridge Investment Research, Inc.
0.3732 %
88,394 0.3732 % 53 302 $
Citadel Securities GP LLC
0.3059 %
72,449 0.3059 % 43 687 $

Company contact information

VBI Vaccines, Inc.

160 2nd Street Floor 3

02142, Cambridge

+

http://www.vbivaccines.com
address VBI Vaccines Inc.(VBIV)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for VBI Vaccines Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6297 USD
Average target price
5 USD
Spread / Average Target
+694.03%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VBI VACCINES INC. Stock VBI Vaccines Inc.
+7.18% 17.9M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.82% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+44.25% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+2.56% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.09% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.16% 18.36B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+22.12% 11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.74% 11.68B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.75% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VBIV Stock
  4. Company VBI Vaccines Inc.